18th International Congress Teaching Courses

18th International Congress Streaming
Content for Teaching Courses

Pricing: MDS Members: $100 USD; MDS Non- Members: $200 USD

Please click here if you would like to purchase this content.

Session 2309: Non-dopaminergic symptomatic medications for the management of Parkinson’s disease

Chairs: Susan Fox
Toronto, ON, Canada
Kjell Fuxe
Stockholm, Sweden

Glutamatergic medications
Paolo Calabresi
Rome, Italy

Mono-aminergic medications
Per Svenningsson
Stockholm, Sweden

Cholinergic medications
Antonio Pisani
Rome, Italy

Learning Objectives
At the conclusion of this session, participants should be better able to:

1. Understand the basic pharmacological mechanisms of glutamate transmission relevant to Parkinson’s disease and the rationale for glutamate antagonists in the treatment of dyskinesia in Parkinson’s disease
2. Understand the pathophysiology of noradrenergic and serotonergic transmission in Parkinson’s disease and the clinical evidence supporting the use of already marketed drugs (eg beta-blockers, antidepressants , L-DOPA, alpha 1 agonists (midodrine), methylphenidate)
3. Understand the pathophysiology of cholinergic transmission relevant to PD and the rationale for drugs such as anticholinergics, nicotinic agents and cholinesterase inhibitors in the management of motor and non-motor symptoms in Parkinson’s disease

Session 2310: Dystonia: A practical approach to diagnosis, measurement and management

Chairs: Cynthia Comella
Chicago, IL, USA
Marina De Koning-Tijssen
Groningen, Netherlands

Diagnosis and pathogenesis of dystonia
William Dauer
Ann Arbor, MI, USA

How to rate dystonia
Cynthia Comella
Chicago, IL, USA

Current medical and surgical treatments for dystonia
Elena Moro
Grenoble, France

Learning Objectives
At the conclusion of this session, participants should be better able to:

1. Discuss the clinical diagnosis and pathogenesis of dystonia
2. Appreciate the usefulness of the rating scales for dystonia
3. Summarize current medical and surgical therapies for dystonia and their applications

Session 3309: Movement disorders and internal medicine

Chairs: Tim Anderson
Christchurch, New Zealand
Roongroj Bhidayasiri
Bangkok, Thailand

Infections and movement disorders
Roongroj Bhidayasiri
Bangkok, Thailand

Endocrine-metabolic disorders and movement disorders
Yih-Ru Wu
Taipei, Taiwan

Cardiovascular diseases and movement disorders
Vladimir Kostić
Belgrade, Serbia

Learning Objectives
At the conclusion of this session, participants should be better able to: 

1. List the movement disorders associated with infections, endocrine-metabolic disorders and cardiovascular diseases
2. Discuss the clinical features and diagnosis of movement disorders associated with infections, endocrine-metabolic-disorders and cardiovascular diseases
3. Discuss the clinical features and diagnosis of movement disorders associated with infections, endocrine-metabolic-disorders and cardiovascular diseases

Session 3310: Addiction and withdrawal of dopamine replacement therapy for Parkinson’s disease

Chairs: Oscar Gershanik
Buenos Aires, Argentina
Sean O’Sullivan
Cork, Ireland

Role of dopaminergic systems in reward mechanisms
Daniel Weintraub
Ardmore, PA, USA

Dopamine dysregulation syndrome
Sean O‘Sullivan
Cork, Ireland

Dopamine agonist withdrawal syndrome
Melissa Nirenberg
New York, NY, USA

Learning Objectives
At the conclusion of this session, participants should be better able to:

1. Understand the biological mechanisms leading to dopamine dysregulation syndrome
including behavioral addictions, impulse control disorders and addiction to L-dopa
2. Recognize and manage addictive and impulsive behaviors associated with the use of dopaminergic drugs in the treatment of Parkinson’s disease
3. Describe risk factors, clinical features and management of dopamine agonist withdrawal syndrome

Session 4309: Gait in parkinsonian syndromes and other movement disorders

Chairs: Nir Giladi
Tel Aviv, Israel
Lynn Rochester
Newcastle upon Tyne, United Kingdom

Pathophysiology of gait in parkinsonian syndromes and other movement disorders
Nir Giladi
Tel Aviv, Israel

Evaluation of gait disorders:
Clinical observation and gait analysis
Evzen Ruzicka
Prague, Czech Republic

Practical approach to management
Lynn Rochester
Newcastle upon Tyne, United Kingdom

Learning Objectives
At the conclusion of this session, participants should be better able to:

1. Understand the physiology of normal gait and the abnormalities in parkinsonian syndromes and other movement disorders
2. Characterize the different patterns of gait disorders and how they can be assessed using
clinical observation and laboratory testing
3. Recognize the different therapeutic interventions for gait disorders in parkinsonian syndromes and other movement disorders from pharmacological options to various exercise/rehabilitation programs

Session 4310: Uncommon treatable movement disorders not to be missed

Chairs: Alberto Albanese
Milan, Italy
Eng-King Tan
Singapore

Uncommon treatable hypokinetic disorders
Eng-King Tan
Singapore
Uncommon treatable hyperkinetic disorders
Alberto Albanese
Milan, Italy
Unusual reversible iatrogenic disorders
Madhuri Behari
New Delhi, India

Learning Objectives
At the conclusion of this session, participants should be better able to:

1. Recognize the clinical features, identify appropriate diagnostic tests, and initiate prompt treatment for hypokinetic disorders
2. Recognize the clinical features, identify appropriate diagnostic tests, and initiate
prompt treatment for hyperkinetic disorders
3. Recognize the clinical features, identify appropriate diagnostic tests, and initiate
prompt treatment for reversible iatrogenic disorders

Session 5310: How to assess patients in clinical trials with experimental therapies for Parkinson’s disease

Chairs: Karl Kieburtz
Rochester, NY, USA
Olle Lindvall
Lund, Sweden

Recruitment strategies and patient selection
Alfonso Fasano
Toronto, ON, Canada

Biochemical and imaging markers
Kenneth Marek
New Haven, CT, USA

Design and critical appraisal of clinical trials
Bernard Ravina
Cambridge, MA, USA

Learning Objectives
At the conclusion of this session, participants should be better able to:

1. Understand how to select the best candidates undergoing experimental therapies for
Parkinson’s disease
2. Choose adequate imaging and laboratory
outcomes
3. Critically appraise the results from the trials
 

Autoimmune movement disorders
Sarosh Irani
Oxford, United Kingdom
Thomas Kimber
Adelaide, SA, Australia

Autoimmune hyper and hypokinetic movement disorders
Thomas Kimber
Adelaide, SA, Australia

Stiff-man syndromes
Hans-Michael Meinck
Heidelberg, Germany

Recognition and treatment principles for autoimmune syndromes of myoclonus and epilepsy
Sarosh Irani
Oxford, United Kingdom

Learning Objectives

1. Learn when to suspect, how to diagnose and treat autoimmune hyperkinetic movement disorders (Sydenham’s chorea, anti-phospholipid syndrome, NMDA- receptor encephalitis)
2. Learn when to suspect, how to diagnose and treat autoimmune hypokinetic movement syndromes (stiff-man syndromes, autoimmune parkinsonism)
3. Learn to recognize the overlap between the phenomenology of movement disorders and myoclonus or seizures caused by immune-mediated encephalitis, and how to diagnose and treat these conditions (e.g, opsoclonus-myoclonus, anti-VGKC/CASPR2/Lgi1 Ab associated encephalitis)

Top